Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Aortic Regurgitation I: Introduction01:15

Aortic Regurgitation I: Introduction

IntroductionAortic regurgitation is characterized by the backward flow of blood from the aorta into the left ventricle during diastole and arises from the improper closure of the aortic valve. This condition results in left ventricular volume overload and can stem from both acute and chronic etiologies, each contributing uniquely to the disease's progression and symptomatology.Acute and Chronic CausesAcute aortic regurgitation often results from events that suddenly impair the integrity of the...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Fabry disease cardiomyopathy: Time for a closer heart rhythm monitoring?

Heart failure reviews·2026
Same author

Micro- and nano-plastics in the coronary circulation and air pollution exposure in ischaemic heart disease presentation.

European heart journal·2026
Same author

A cone opsin double knockout mouse reveals long-term cone survival and provides a platform for gene therapy.

Research square·2026
Same author

Balloon-Expandable Versus Self-Expanding Valves in Patients With Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same author

Computed Tomography Sizing Algorithm for Transcatheter Aortic Valve Implantation in Bicuspid Valve: Results From the CASPER Registry.

The Canadian journal of cardiology·2026
Same author

Pre-Existing and New-Onset Atrial Fibrillation in Patients Undergoing Transcatheter Aortic Valve Implantation.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

相关实验视频

Updated: Jul 20, 2026

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves
07:12

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves

Published on: August 23, 2011

15.7K

与克雷亚大动脉系统的初始经验 - - 这是一项首次对人体进行的研究.

Carlos Calderas1, Maurizio Taramasso2, Jimmy Levy1

  • 1Policlínica Metropolitana, Caracas, Venezuela.

AsiaIntervention
|March 21, 2025
PubMed
概括

新的Crea大动脉 (CAV) 系统在患有严重大动脉狭窄症的高风险患者中成功植入和表现. 早期的安全数据显示,六个月后没有重大不良事件,支持进一步的临床评估.

更多相关视频

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.0K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

13.9K

相关实验视频

Last Updated: Jul 20, 2026

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves
07:12

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves

Published on: August 23, 2011

15.7K
Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.0K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

13.9K

科学领域:

  • 心血管医学 心血管医学
  • 干预心脏病学 干预心脏病学
  • 医疗器械 医疗器械

背景情况:

  • 过导管大动脉植入 (TAVI) 为严重的大动脉狭窄 (AS) 提供了一种微创的方法.
  • 克里亚大动脉 (Crea Aortic Valve,简称CAV) 是一款具有前临床成果的试验性自我扩张的跨导管心脏.

研究的目的:

  • 评估新型CAV系统的技术成功,设备性能和早期安全性.
  • 在对患有严重AS的患者进行首次人体研究中评估CAV系统.

主要方法:

  • 对三名高风险AS患者的前性评估,这些患者在使用CAV系统进行TAVI.
  • 评估使用门学术研究联盟 (VARC) - 3标准,计算机断层扫描血管学和连续的胸前心声学 (TTE).
  • 在基线,手术后,以及1个月和6个月后续检查时监测血液动力学参数和准膜泄漏 (PVL).

主要成果:

  • 在所有三名患者中都取得了成功的CAV植入,具有良好的设备可用性和定位.
  • 血液动力学改善包括降低Vmax (<2 m/s) 和平均梯度 (<10 mmHg),PVL微不足道.
  • 一名患者因心房阻塞需要永久性起器;在6个月内没有发生中风,心力衰竭或功能衰竭.

结论:

  • 根据VARC-3标准,CAV系统满足了技术成功和性能的主要终点.
  • 在这项初始人体研究中,该设备在早期的安全性和有效性方面表现良好.
  • 需要进行更大规模的临床试验,以进一步确定CAV系统的疗效和安全性.